Claudin 18.2 - a GLOW-ing biomarker in Gastric Cancer - Part 1 of 2
Update: 2025-05-06
Description
In this episode of MedOncNow, Dr. Brandon Sheffield explores the role of Claudin 18.2 as a biomarker in gastroesophageal junction (GEJ) and gastric cancers. He discusses key considerations for testing and the evolving implications for biomarker-driven treatment in gastric cancer.
This conversation is especially timely as ASTELLAS is currently funding Claudin 18.2 testing as part of the Gastric Cancer Biomarker Workflow initiative.
Access to Zolbetuximab from ASTELLAS will follow in May 2025.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
